Communications Biology (Oct 2024)
Golgi-localized Ring Finger Protein 121 is necessary for MYCN-driven neuroblastoma tumorigenesis
- Belamy B. Cheung,
- Ritu Mittra,
- Jayne Murray,
- Qian Wang,
- Janith A. Seneviratne,
- Mukesh Raipuria,
- Iris Poh Ling Wong,
- David Restuccia,
- Andrew Gifford,
- Alice Salib,
- Selina Sutton,
- Libby Huang,
- Parisa Vahidi Ferdowsi,
- Joanna Tsang,
- Eric Sekyere,
- Chelsea Mayoh,
- Lin Luo,
- Darren L. Brown,
- Jennifer L. Stow,
- Shizhen Zhu,
- Richard J. Young,
- Benjamin J. Solomon,
- Stephane Chappaz,
- Benjamin Kile,
- Andrew Kueh,
- Marco J. Herold,
- Douglas J. Hilton,
- Tao Liu,
- Murray D. Norris,
- Michelle Haber,
- Daniel R. Carter,
- Michael W. Parker,
- Glenn M. Marshall
Affiliations
- Belamy B. Cheung
- Children’s Cancer Institute Australia for Medical Research, Lowy Cancer Research Centre, UNSW Sydney
- Ritu Mittra
- Children’s Cancer Institute Australia for Medical Research, Lowy Cancer Research Centre, UNSW Sydney
- Jayne Murray
- Children’s Cancer Institute Australia for Medical Research, Lowy Cancer Research Centre, UNSW Sydney
- Qian Wang
- Children’s Cancer Institute Australia for Medical Research, Lowy Cancer Research Centre, UNSW Sydney
- Janith A. Seneviratne
- Children’s Cancer Institute Australia for Medical Research, Lowy Cancer Research Centre, UNSW Sydney
- Mukesh Raipuria
- Children’s Cancer Institute Australia for Medical Research, Lowy Cancer Research Centre, UNSW Sydney
- Iris Poh Ling Wong
- Children’s Cancer Institute Australia for Medical Research, Lowy Cancer Research Centre, UNSW Sydney
- David Restuccia
- Children’s Cancer Institute Australia for Medical Research, Lowy Cancer Research Centre, UNSW Sydney
- Andrew Gifford
- Children’s Cancer Institute Australia for Medical Research, Lowy Cancer Research Centre, UNSW Sydney
- Alice Salib
- Children’s Cancer Institute Australia for Medical Research, Lowy Cancer Research Centre, UNSW Sydney
- Selina Sutton
- Children’s Cancer Institute Australia for Medical Research, Lowy Cancer Research Centre, UNSW Sydney
- Libby Huang
- Children’s Cancer Institute Australia for Medical Research, Lowy Cancer Research Centre, UNSW Sydney
- Parisa Vahidi Ferdowsi
- Children’s Cancer Institute Australia for Medical Research, Lowy Cancer Research Centre, UNSW Sydney
- Joanna Tsang
- Children’s Cancer Institute Australia for Medical Research, Lowy Cancer Research Centre, UNSW Sydney
- Eric Sekyere
- Children’s Cancer Institute Australia for Medical Research, Lowy Cancer Research Centre, UNSW Sydney
- Chelsea Mayoh
- Children’s Cancer Institute Australia for Medical Research, Lowy Cancer Research Centre, UNSW Sydney
- Lin Luo
- Institute for Molecular Bioscience, University of Queensland
- Darren L. Brown
- Institute for Molecular Bioscience, University of Queensland
- Jennifer L. Stow
- Institute for Molecular Bioscience, University of Queensland
- Shizhen Zhu
- Department of Biochemistry and Molecular Biology, Cancer Center and Center for Individualized Medicine, Mayo Clinic
- Richard J. Young
- Peter MacCallum Cancer Centre
- Benjamin J. Solomon
- Peter MacCallum Cancer Centre
- Stephane Chappaz
- Anatomy & Developmental Biology, Monash University
- Benjamin Kile
- Faculty of Health and Medical Sciences at the University of Adelaide
- Andrew Kueh
- Blood Cells and Blood Cancer Division, Walter and Eliza Hall Institute
- Marco J. Herold
- Blood Cells and Blood Cancer Division, Walter and Eliza Hall Institute
- Douglas J. Hilton
- Blood Cells and Blood Cancer Division, Walter and Eliza Hall Institute
- Tao Liu
- Children’s Cancer Institute Australia for Medical Research, Lowy Cancer Research Centre, UNSW Sydney
- Murray D. Norris
- Children’s Cancer Institute Australia for Medical Research, Lowy Cancer Research Centre, UNSW Sydney
- Michelle Haber
- Children’s Cancer Institute Australia for Medical Research, Lowy Cancer Research Centre, UNSW Sydney
- Daniel R. Carter
- Children’s Cancer Institute Australia for Medical Research, Lowy Cancer Research Centre, UNSW Sydney
- Michael W. Parker
- ACRF Facility for Innovative Cancer Drug Discovery and Department of Biochemistry and Pharmacology, Bio21 Molecular Science and Biotechnology Institute, The University of Melbourne, Parkville
- Glenn M. Marshall
- Children’s Cancer Institute Australia for Medical Research, Lowy Cancer Research Centre, UNSW Sydney
- DOI
- https://doi.org/10.1038/s42003-024-06899-8
- Journal volume & issue
-
Vol. 7,
no. 1
pp. 1 – 13
Abstract
Abstract MYCN amplification predicts poor prognosis in childhood neuroblastoma. To identify MYCN oncogenic signal dependencies we performed N-ethyl-N-nitrosourea (ENU) mutagenesis on the germline of neuroblastoma-prone TH-MYCN transgenic mice to generate founders which had lost tumorigenesis. Sequencing of the mutant mouse genomes identified the Ring Finger Protein 121 (RNF121 WT ) gene mutated to RNFM158R associated with heritable loss of tumorigenicity. While the RNF121WT protein localised predominantly to the cis-Golgi Complex, the RNF121 M158R mutation in Helix 4 of its transmembrane domain caused reduced RNF121 protein stability and absent Golgi localisation. RNF121WT expression markedly increased during TH-MYCN tumorigenesis, whereas hemizygous RNF121 WT gene deletion reduced TH-MYCN tumorigenicity. The RNF121WT-enhanced growth of MYCN-amplified neuroblastoma cells depended on RNF121WT transmembrane Helix 5. RNF121WT directly bound MYCN protein and enhanced its stability. High RNF121 mRNA expression associated with poor prognosis in human neuroblastoma tissues and another MYC-driven malignancy, laryngeal cancer. RNF121 is thus an essential oncogenic cofactor for MYCN and a target for drug development.